Just how do they expect to be taken seriously in a biotech article when investors know more than they do about what they are writing about? He continually posits the success at ASH for 145 but still searches for a way to bash the stock. This should not be legal or allowed, let alone printed.
And the soft basher lower price target technical guy shows up to blah some conversation, thanks again stevo for your brilliant insights and valuable contributions.
This stock is ready to rumble as we are clearly on the CHMP schedule. Look at the meeting notes, probably will post tomorrow. LOI was accepted months ago and the data clearly is not that complicated so I say:
SHOW ME THE MONEY BABY!
Results were positive and PII and PIII are right around the corner. If we saw a positive response rate as was indicated, how can this stock trade just above it's annual low. Manipulation can only go so far before the good news rolls the shorts upside down. I've got plenty of time.....
Really? None of us here on this board or any other really care, none of us. Yell your trades from your rooftop please, but remember that we all worry more about ourselves and don't worry/care about you at all..... Really~
As I believe, a special dividend would crush any naked shorting, and as Grindle points out maybe the stock hasn't been largely naked shorted but a special dividend would absolutely force a cover, not a complete short cover but a noticeable finger in the eye of shorts what do you think?
We have all been waiting for some Z news but I don't think anyone would have expected this , by cleanup maneuver I think you meant cleaning up the balance sheet for future acquisition of Ampio right? Anyways this asset has not rewarded us longs yet as we are up a paltry .11 cents as of this writing, seems LAME and I want my proportional worth in SP appreciation, if AMPE announced a special dividend then the shorts would all have to report their naked shares and be subject to immediate repurchase of cover shares to engage the special dividend wouldn't that be awesome!
80% projected ownership and retention, how does Ampio and it's shareholders benefit, if the asset were sold off rather than spun wouldn't we have recieved a premium?
Oh yea? what a brilliant downgrade: the supposed analyst reiterates his $20 price target but says neutral because of a limited amount of news headlines over the coming year, so apparently he is neutral on his projected 54% gain he is forecasting, yea many people would be neutral on a big gain like that, yea right whataguy.
I can get behind a reasonable statement like this, reasonable.
Soft bashing an otherwise good stock has it's perils, as long as you and others remain reasonable, people who actually invest and not trade will appreciate this.
Gee, thanks for putting this back on top for people to digest, people that is who don't care at all about your trades, people who value a great company based on succesful results from a cancer drug, people who want to make money by investing and not posting #$%$ to suit the "other" side of the trade.
You sound a little bitter there pup nay I say even depressed, sorry for your loss, and my condolences. I pray for you and your family in this time of need.
Forgot to mention: LS the new standard of care diagnostic is here-- and soon to be sold to radiologists all over the country and saving lives in the process. Watch for analyst upgrades to follow and remember we were at over $3 per share before we were fast tracked just getting back to highs would be over 50% return.
That's what I was wondering, he's bashed every and I mean every one of my stocks and my portfolio is full of good stocks, but he'll offer us no apology, never~
I thought the call was brief and direct and to the point. Highlights in my ear were: we will hear about Zertane by year's end, ongoing lengthy talks with big pharma, plenty of cash to fund trials and operations, facilities management for future production planned and executed, and a healthy relationship with the FDA on trial design and implementation for a real strong shot at success on both Ampion and Optina for the shorter length trials coming up leading to future commercialization. Did anyone hear anything bad, in any way anything? How will the short shills spin this on the next slam article? Your thoughts very welcome~